Semaglutide analogues and the medicines that share their pathway

You searched 'semaglutide analogues' — here is what is actually going on

Imagine you have spent an hour reading about weight-loss injections and you keep hitting the same cluster of terms: GLP-1, semaglutide, analogue, agonist, receptor. They sound interchangeable, but they are not. A hormone analogue is a molecule designed to behave like the original hormone while being chemically altered enough to survive digestion or circulation far longer. GLP-1 (glucagon-like peptide-1) is released naturally from cells in the gut after eating; it signals fullness to the brain, slows the passage of food from the stomach and prompts the pancreas to release insulin. The natural hormone lasts only a couple of minutes. Semaglutide is a version of that hormone re-engineered to last about a week in the body, which is why a once-weekly injection is enough. Oral semaglutide, approved by the MHRA in June 2026 as Wegovy tablets, extends that further by adding a small absorption-enhancing molecule, and how semaglutide's solubility is modified to make that oral absorption possible is worth understanding if you are curious about the science. Semaglutide's mechanism, licensed uses and UK status are covered in more detail if you want to go deeper on that specific molecule.

Liraglutide is an older GLP-1 analogue requiring daily injections; it is licensed for weight management in the UK as Saxenda, though nume does not dispense it. These structural differences (once-daily, once-weekly, or twice-weekly dosing in the case of some diabetes formulations) are a direct consequence of each analogue's molecular design.

Where tirzepatide sits among semaglutide's closest relatives

Tirzepatide, sold in the UK as Mounjaro by Eli Lilly, is often grouped with semaglutide analogues in online searches, and the comparison is reasonable: both are GLP-1 receptor agonists, both are once-weekly subcutaneous injections, and both are licensed for weight management in UK adults. The meaningful difference is that tirzepatide also activates the GIP receptor, a second gut-hormone pathway involved in appetite and metabolism. That dual action is why NICE, in appraising tirzepatide (TA1026), and the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. Neither result means one medicine is right for everyone; a prescriber weighs individual circumstances.

For those wondering about cost, our treatment page sets out what private clinical assessment and dispensing through a GPhC-registered pharmacy involves, the full picture, not just the headline figure. And if you want to explore Wegovy specifically, including how the injection and tablet versions compare, that covers the ground clearly.

One detail worth knowing: Ozempic is also semaglutide, but it carries a diabetes licence, not a weight-management one. Rybelsus is oral semaglutide at diabetes doses. Searching for either as a weight-loss treatment leads to the wrong product; the differences between semaglutide products licensed in the UK are easy to confuse, and clarifying them matters for safety.

Licensed eligibility in the UK: what the GLP-1 analogues share and where they diverge

All weight-management GLP-1 analogues available in the UK are licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. Beyond those headline criteria, the products differ. Wegovy (semaglutide 2.4 mg injection) is recommended by NICE (TA875) specifically within specialist weight management services and for no more than two years. Tirzepatide (NICE TA1026) carries different comorbidity requirements for NHS access and is now entering GP prescribing under the 2026/27 contract. The Wegovy tablet, approved by the MHRA on 11 June 2026, carries its own eligibility conditions and is not yet appraised by NICE, meaning it is currently available via private prescription only.

In a private setting, a prescriber assesses the full picture: which analogue suits this person, at what starting dose, alongside what monitoring. BMI alone is not the whole answer, and the prescriber's role is to work through the rest. Our clinical team handles those assessments personally, and every consultation is reviewed by a named GPhC-registered Independent Prescriber on the day it is submitted.

Side effects, safety signals and what to watch for across the class

GLP-1 analogues share a broadly similar side-effect profile because they act on the same receptor. Gastrointestinal effects are the most common: nausea, loose stools, constipation, reflux and reduced appetite. Most people find these are most noticeable in the first days after starting treatment or after a dose step, then settle. They are rarely a reason to stop, but they are worth planning around.

Two signals warrant particular attention across the class. The MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; severe stomach pain that spreads to the back, with or without vomiting, needs prompt medical assessment rather than a wait-and-see approach. Gallbladder problems are also recognised across the class. Side effects of semaglutide in more detail covers the full profile for that molecule. Patients and carers can report any suspected side effect through the MHRA Yellow Card scheme, which also accepts reports about suspect sellers, an important channel given the volume of counterfeit GLP-1 pens that have entered the UK market.

On delivery: if treatment is approved through nume and dispatched, it arrives via DPD the next working day in plain, unbranded packaging with a tracking link sent in advance. The pen itself is Lilly's KwikPen for Mounjaro or Novo Nordisk's pre-filled pen for Wegovy. Both require refrigeration on arrival. Storage and handling for semaglutide products explains what to do if your pen has been out of the fridge. If you would like to understand whether one of these medicines might be suitable for you, checking your eligibility starts with a free consultation, reviewed the same day by a prescriber, not software.